The 392-page report examines a wide range of topics in relation to enzymes, including chapters on global economic conditions; outlook overviews for a variety of sectors (world manufacturing, food and beverage, chemicals, cleaning products, pharmaceuticals, and animal feed); and a seven -part analysis of key enzyme technologies. World enzyme demand increased at a nearly double-digit pace from 2003 to 2008, helped in large part by the rapid increase in world energy prices (which made enzymerelated processes and products more cost effective and facilitated the legislation of a rapid expansion of the fuel ethanol market, particularly in the United States) and the successful launch of several enzyme-containing pharmaceuticals.
704 inform November 2009, Vol. 20 (11) Union) member states, risk managers, and She also expressed criticism of some of rapid expansion of the fuel ethanol market, representatives from stakeholders includ- EFSA’s scientific opinions on GMO. particularly in the United States) and the ing industry, consumer, and environmental Presenting the views of EU farmers, successful launch of several enzyme-con- groups from the EU and beyond. COPA-COGECA’s Director of Commodi- taining pharmaceuticals. With the world in EFSA Executive Director Catherine ties and Trade, Arnaud Petit, said farmers an economic downturn in 2009, however, Geslain-Lanéelle opened the conference wanted to preserve the option of choosing the market for enzymes has become much by reaffirming EFSA’s role as a provider between GM, conventional, and organic more challenging, and growth going of independent scientific advice on GMO. farming. (COPA is the Committee of Pro- forward will moderate significantly. “EFSA is neither pro-GMO nor anti-GMO,” fessional Agricultural Organisations, and Through 2013 world enzyme demand she said. She acknowledged that there exists COGECA is the General Confederation will average annual increases of 6.3%, led a significant divergence of opinion among of Agricultural Cooperatives in the Euro- by pharmaceutical and biocatalyst enzymes, various actors in the field of GMO in the pean Union. The biotechnology industry, both of which will be less susceptible to the EU. “We are here not only to inform but represented by Willy De Greef of Europa- effects of lowered global economic activ- also to listen and learn. We want to get as Bio (the European Association for Bioin- ity. Diagnostics enzyme demand will also wide a range of views and experiences as dustries), asked for the existing experiences fare well due to expanded access to medical possible,” she said. of the safe use of GM crops to be taken care in developing countries, and the advent The first day’s presentations came into consideration in EU risk assessment of health care reform in the United States. from members of EFSA’s GMO Panel and and called for a clearer distinction between With pharmaceutical companies having dif- the GMO Unit, who discussed the legal risk research and risk assessment. ficulty bringing new small-molecule drugs framework for GMO in the EU, as well as to market, biotechnology will continue some of EFSA’s updated guidelines on the risk assessment of GM plants, developed in Report examines to gain in importance, helping to sustain demand for research and biotechnology the context of mandates from the European Commission (EC). world enzymes enzymes. Among the industrial enzyme markets, Presenters examined environmen- tal risk assessment (ERA) of GM plants market animal feed and ethanol production will both achieve above-average advances, as a complex issue whose ongoing devel- In September, business research company while the food and beverage market will opments have prompted updates in EFSA The Freedonia Group (Cleveland, Ohio, grow at a slower, but healthy pace. Animal guidelines. GMO Panel members Salva- USA) released the report World Enzymes feed enzymes will achieve their fastest tore Arpaia and Jeremy Swe
Pages to are hidden for
"Report examines world enzymes market"Please download to view full document